8-K: United Therapeutics Reports Record Revenue Growth in Third Quarter 2024

United Therapeutics announced a 23 percent year-over-year revenue increase in the third quarter of 2024, reaching $748.9 million.

Summary

• United Therapeutics reported a strong third quarter in 2024, with total revenues reaching $748.9 million, a 23% increase compared to $609.4 million in the same quarter of 2023.
• Net income for the quarter was $309.1 million, up from $267.6 million in the prior year, representing a 16% increase.
• The company's earnings per basic share rose to $6.93, compared to $5.71 in the third quarter of 2023, and diluted earnings per share increased to $6.39 from $5.38.
• Tyvaso product sales were a major driver of growth, with total Tyvaso revenues increasing by 33% to $433.8 million.
• Tyvaso DPI sales reached $274.6 million, a 34% increase, while nebulized Tyvaso sales were $159.2 million, a 32% increase.
• Remodulin revenues decreased slightly by 2% to $128.3 million, while Orenitram revenues increased by 23% to $113.2 million.
• Unituxin revenues also saw a 19% increase, reaching $61.1 million.
• The company accrued a $65.1 million liability related to ongoing litigation with Sandoz Inc.
• United Therapeutics repurchased 3,547,374 shares of its common stock under an accelerated share repurchase agreement.

Sentiment

Score: 8

Explanation: The document conveys a very positive sentiment due to the strong revenue growth, increased profitability, and promising pipeline. The litigation accrual is a minor negative, but the overall tone is optimistic.

Positives

• The company achieved record revenue for the sixth consecutive quarter.
• Tyvaso continues to be a significant growth driver, with strong uptake in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
• The company is seeing increased commercial utilization of its products following the implementation of the Part D redesign under the Inflation Reduction Act.
• The company has a strong pipeline of clinical trials and regulatory events expected in the coming years.
• The company's share repurchase program has reduced the number of outstanding shares.

Negatives

• Remodulin revenues decreased by 2% due to a decline in international sales.
• The company accrued a $65.1 million liability related to ongoing litigation with Sandoz Inc.
• Research and development expenses increased due to expenditures related to manufactured organ and organ alternative projects.
• Selling, general, and administrative expenses increased significantly due to a litigation accrual and increased personnel expenses.

Risks

• The company faces ongoing litigation with Sandoz Inc., which could result in additional financial liabilities.
• The company's future performance is subject to the success of its clinical trials and regulatory approvals.
• The company's financial results could be impacted by changes in healthcare regulations and pricing pressures.
• The company's reliance on Tyvaso for growth makes it vulnerable to potential competition or market changes.

Future Outlook

United Therapeutics anticipates a multi-year cascade of clinical data reads and regulatory events starting in 2025, which are expected to drive growth. The company is focused on the TETON, ADVANCE OUTCOMES, and miroliverELAP studies, as well as the launch of the UKidney human clinical program.

Management Comments

• Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer, stated she is proud of the close to 1,300 Unitherians who have contributed to another record revenue quarter and reaching a $3 billion annual revenue run rate.
• Martine Rothblatt also noted that 2025 marks the start of a multi-year cascade of clinical data reads and regulatory events that should continue to propel the company's growth.
• Michael Benkowitz, President and Chief Operating Officer, highlighted the outstanding financial results and the increasing demand for the company's innovative products.
• Michael Benkowitz also noted that Tyvaso remains the biggest near-term growth driver.

Industry Context

The strong revenue growth reported by United Therapeutics reflects the increasing demand for treatments for pulmonary hypertension and high-risk neuroblastoma. The company's focus on innovative therapies and its pipeline of clinical trials position it well within the competitive pharmaceutical and biotechnology landscape.

Comparison to Industry Standards

• United Therapeutics' 23% revenue growth significantly exceeds the average growth rate for established pharmaceutical companies, which typically see single-digit growth.
• The 33% growth in Tyvaso revenues is particularly impressive, indicating strong market adoption and demand for this product.
• Compared to companies like Actelion (acquired by J&J) which also focused on pulmonary hypertension, United Therapeutics is demonstrating a more robust growth trajectory in recent quarters.
• The company's investment in research and development, particularly in manufactured organs, is a unique approach compared to many of its peers, which primarily focus on drug development.
• The litigation accrual of $65.1 million is a significant event, and the impact will need to be monitored against industry benchmarks for similar legal challenges.

Legal Proceedings

• The company accrued a $65.1 million liability related to ongoing litigation with Sandoz Inc.

Stakeholder Impact

• Shareholders will benefit from the strong financial performance and share repurchase program.
• Employees may benefit from the company's growth and success.
• Patients will benefit from the company's continued development of innovative therapies.
• The company's suppliers and partners will benefit from the increased business activity.

Next Steps

• The company will continue to progress its clinical trials, including the TETON, ADVANCE OUTCOMES, and miroliverELAP studies.
• The company plans to file an investigational new drug application for its UKidney program.
• The company will host a webcast to discuss the third quarter 2024 financial results on October 30, 2024.

Key Dates

Keywords

United Therapeutics, Tyvaso, Pulmonary Hypertension, Revenue Growth, Clinical Trials, Pharmaceuticals, Biotechnology, Net Income, Tyvaso DPI, Orenitram